Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGSNASDAQ:EDITNASDAQ:ENTANASDAQ:NLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$5.45-6.5%$9.93$3.76▼$46.80$33.32M2.72188,287 shs124,251 shsEDITEditas Medicine$1.54-4.3%$1.48$0.91▼$6.69$128.91M2.162.58 million shs1.08 million shsENTAEnanta Pharmaceuticals$5.58-1.6%$6.15$4.09▼$17.24$119.04M0.69286,898 shs179,075 shsNLTXNeoleukin Therapeutics$15.37-0.5%$13.94$2.03▼$14.36$144.45M1.1150,104 shs152,822 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-6.52%+16.45%-43.58%-82.09%-73.70%EDITEditas Medicine-4.35%+19.84%+21.26%+11.59%-71.21%ENTAEnanta Pharmaceuticals-1.59%+9.41%-4.78%+0.90%-56.81%NLTXNeoleukin Therapeutics-0.45%+33.77%+10.10%+2.06%-50.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics3.9085 of 5 stars3.52.00.04.82.21.70.6EDITEditas Medicine4.0157 of 5 stars3.03.00.04.22.61.71.3ENTAEnanta Pharmaceuticals3.9957 of 5 stars3.41.00.04.73.04.20.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.001,184.40% UpsideEDITEditas Medicine 2.07Hold$6.83343.72% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25209.14% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALGS, ENTA, EDIT, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/11/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.002/11/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.00 ➝ $21.002/11/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.95M8.45N/AN/A$30.65 per share0.18EDITEditas Medicine$32.31M3.99N/AN/A$4.27 per share0.36ENTAEnanta Pharmaceuticals$66.59M1.79N/AN/A$5.24 per share1.06NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$87.68M-$20.90N/AN/AN/A-1,283.19%-114.34%-64.58%5/6/2025 (Estimated)EDITEditas Medicine-$153.22M-$2.88N/AN/AN/A-340.96%-80.13%-50.99%5/6/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%5/5/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ALatest ALGS, ENTA, EDIT, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025EDITEditas Medicine-$0.52N/AN/AN/A$0.79 millionN/A5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80N/AN/AN/A$0.33 millionN/A5/5/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.16N/AN/AN/A$15.96 millionN/A3/10/2025Q4 2024ALGSAligos Therapeutics-$2.63-$13.08-$10.45-$13.08$0.43 million$0.63 million3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A3.813.81EDITEditas MedicineN/A3.753.75ENTAEnanta PharmaceuticalsN/A5.475.47NLTXNeoleukin TherapeuticsN/A15.3315.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%EDITEditas Medicine71.90%ENTAEnanta Pharmaceuticals94.99%NLTXNeoleukin Therapeutics52.37%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics8.75%EDITEditas Medicine1.90%ENTAEnanta Pharmaceuticals13.89%NLTXNeoleukin Therapeutics1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million3.27 millionNo DataEDITEditas Medicine23083.71 million80.98 millionOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataALGS, ENTA, EDIT, and NLTX HeadlinesRecent News About These CompaniesNeoleukin Therapeutics (NASDAQ:NLTX) Stock Price Up 8.3% - Here's What HappenedApril 6, 2025 | marketbeat.com(NGNE) Proactive StrategiesOctober 18, 2024 | news.stocktradersdaily.comNeurogene concludes merger deal with Neoleukin TherapeuticsDecember 20, 2023 | pharmaceutical-technology.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%September 26, 2023 | dhakatribune.comNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comInvesting in Neoleukin Therapeutics Inc. [NLTX]: What You Must KnowAugust 21, 2023 | knoxdaily.comNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXAugust 1, 2023 | markets.businessinsider.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 28, 2023 | finance.yahoo.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 26, 2023 | benzinga.comAnalysts review Neoleukin Therapeutics Inc.’s ratingJuly 26, 2023 | knoxdaily.comALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCFJuly 24, 2023 | kentuckytoday.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 24, 2023 | 247wallst.comAn Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price GrowthJuly 19, 2023 | knoxdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentFundamentally Sound, These 5 Stocks Sold Off AnywayBy Thomas Hughes | April 23, 2025View Fundamentally Sound, These 5 Stocks Sold Off AnywayJPMorgan: The 'NVIDIA of Banking' Poised for More Gains?By Gabriel Osorio-Mazilli | March 28, 2025View JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?Top 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing MarketOil Prices Are Tanking—These 3 Plays Could Fuel Your GainsBy Gabriel Osorio-Mazilli | April 9, 2025View Oil Prices Are Tanking—These 3 Plays Could Fuel Your GainsALGS, ENTA, EDIT, and NLTX Company DescriptionsAligos Therapeutics NASDAQ:ALGS$5.45 -0.38 (-6.52%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.77 +0.32 (+5.87%) As of 04/25/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$1.54 -0.07 (-4.35%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.51 -0.03 (-1.95%) As of 04/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$5.58 -0.09 (-1.59%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.58 0.00 (-0.09%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Neoleukin Therapeutics NASDAQ:NLTX$15.37 -0.07 (-0.45%) As of 04/24/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
